Lithium-induced parathyroid dysfunction: A new case

Nair, C. P. P.; Ramachandran, Riju; Jacob, Pradeep; Babu, Merin

doi:10.4103/2230-8210.117223

Cited by 15 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mitotic activity in excess of 5 mitoses per 50 high power microscopic fields, in combination with the presence of foci of coagulative necrosis and macronucleoli, has been proposed as a triad to label parathyroid lesions with a high risk of malignant behavior, in terms of disease recurrence (Bondenson et al 1993). The presence of atypical mitosis and focal areas of necrosis, though considered as criteria of malignancy, has also been described in a minority of atypical parathyroid adenomas (Katz et al 2012, Ricci et al 2012, Nair et al 2013, Ramaswamy et al 2017, Ryhänen et al 2017, Pal et al 2018, Silva-Figueroa et al 2018.…”

Section: :7mentioning

confidence: 99%

Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors

Cetani

Marcocci

Torregrossa

et al. 2019

Endocrine-Related Cancer

111

124

View full text Add to dashboard Cite

Atypical parathyroid adenomas represent a group of intermediate form of parathyroid neoplasms of uncertain malignant potential which show some atypical histological features that represent a challenge for the differential diagnosis with parathyroid carcinomas. They may occur as sporadic or as a part of hereditary syndromes. The molecular signature of these neoplasms is still unknown and the germline CDC73 mutations appears to be the most common anomaly in this setting suggesting that these cases might represent variants of the hyperparathyroidism-jaw tumor syndrome. The identification of markers predicting the outcome is of great importance to guide an adequate postoperative monitoring and, the same time, relieve of the anxiety of relatively strict monitoring patients not at risk. This review will summarize the current knowledge of the clinical, biochemical, molecular and histological profile of atypical parathyroid adenomas.

show abstract

Section: :7mentioning

confidence: 99%

Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors

Cetani

Marcocci

Torregrossa

et al. 2019

Endocrine-Related Cancer

111

124

View full text Add to dashboard Cite

show abstract

“…Lithium treatment was also closely associated with hyperparathyroidism and hypercalcaemia. A case report revealed that a 28-year-old female patient who receiving Li 2 CO 3 for bipolar mood disorder for at least 2 years developed hyperparathyroidism (Nair et al, 2013). In a cohort study, it was found that bipolar patients with lithium treatment had higher odds of hypercalcaemia as compared to those not receiving lithium treatment (Meehan et al, 2018).…”

Section: Challenge For the Use Of Lithiummentioning

confidence: 99%

The Skeletal-Protecting Action and Mechanisms of Action for Mood-Stabilizing Drug Lithium Chloride: Current Evidence and Future Potential Research Areas

Wong

Chin

2020

Front. Pharmacol.

View full text Add to dashboard Cite

Lithium, the lightest natural-occurring alkali metal with an atomic number of three, stabilizes the mood to prevent episodes of acute manic and depression. Multiple lines of evidence point to lithium as an anti-suicidal, anti-viral, anti-cancer, immunomodulatory, neuroprotective and osteoprotective agent. This review article provides a comprehensive review of studies investigating the bone-enhancing effects of lithium and its possible underlying molecular mechanisms. Most of the animal experimental studies reported the beneficial effects of lithium in defective bones but not in healthy bones. In humans, the effects of lithium on bones remain heterogeneous. Mechanistically, lithium promotes osteoblastic activities by activating canonical Wingless (Wnt)/beta (b)-catenin, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) and bone morphogenetic protein-2 (BMP-2) transduction pathways but suppresses osteoclastic activities by inhibiting the receptor activator of nuclear factor-kappa B (RANK)/receptor activator of nuclear factor-kappa B ligand (RANKL)/osteoprotegerin (OPG) system, nuclear factorkappa B (NF-kB), mitogen-activated protein kinase (MAPK), and calcium signaling cascades. In conclusion, lithium confers protection to the skeleton but its clinical utility awaits further validation from human clinical trials.

show abstract

“…Lithium, which has been in clinical use since 1950 [1-2], is one of the cornerstone treatments for bipolar disorder. Although lithium salts are known to disrupt thyroid function [3], lithium-induced parathyroid dysfunction is rare.…”

Section: Discussionmentioning

confidence: 99%

Lithium-induced Hyperparathyroidism and Hypercalcemia

Naramala

Dalal²,

Adapa³

et al. 2019

Cureus

View full text Add to dashboard Cite

Lithium is one of the mainstays of treatment for bipolar disorder. Chronic lithium therapy can rarely lead to hypercalcemia secondary to lithium-induced hyperparathyroidism. We present a 66-year-old female patient with bipolar disorder on lithium therapy presenting with hypercalcemia. We discussed the pathophysiology and management of hyperparathyroidism and hypercalcemia in patients on chronic lithium therapy.

show abstract

Lithium-induced parathyroid dysfunction: A new case

Cited by 15 publications

References 9 publications

Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors

Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors

The Skeletal-Protecting Action and Mechanisms of Action for Mood-Stabilizing Drug Lithium Chloride: Current Evidence and Future Potential Research Areas

Lithium-induced Hyperparathyroidism and Hypercalcemia

Contact Info

Product

Resources

About